186 related articles for article (PubMed ID: 24662309)
1. Immunomodulatory effects of voriconazole and caspofungin on human peripheral blood mononuclear cells stimulated by Candida albicans and Candida krusei.
Fidan I; Yesilyurt E; Kalkanci A; Aslan SO; Sahin N; Ogan MC; Dizbay M
Am J Med Sci; 2014 Sep; 348(3):219-23. PubMed ID: 24662309
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activity against Candida albicans of nikkomycin Z in combination with caspofungin, voriconazole or amphotericin B.
Sandovsky-Losica H; Shwartzman R; Lahat Y; Segal E
J Antimicrob Chemother; 2008 Sep; 62(3):635-7. PubMed ID: 18490373
[No Abstract] [Full Text] [Related]
3. In vitro biofilm characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates.
Shuford JA; Piper KE; Steckelberg JM; Patel R
Diagn Microbiol Infect Dis; 2007 Mar; 57(3):277-81. PubMed ID: 17141454
[TBL] [Abstract][Full Text] [Related]
4. Generation of mutants in Candida albicans with reduced susceptibility to caspofungin: influence on other antifungal products.
Soler L; Rodriguez JC; Belda S; Cremades R; Ruiz-Garcia M; Lopez P; Royo G
J Chemother; 2010 Aug; 22(4):283-4. PubMed ID: 20685636
[No Abstract] [Full Text] [Related]
5. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
6. Effects of caspofungin, Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSF-stimulated PMNs.
Salvenmoser S; Seidler MJ; Dalpke A; Müller FM
FEMS Immunol Med Microbiol; 2010 Oct; 60(1):74-7. PubMed ID: 20626764
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of voriconazole as a triazole derivative and caspofungin as an echinocandin were compared with those of some antifungal agents against Candida species isolated from clinical specimens.
Ozçelik B; Kaynak F; Cesur S; Sipahi B; Sultan N
Jpn J Infect Dis; 2007 Sep; 60(5):302-4. PubMed ID: 17881873
[TBL] [Abstract][Full Text] [Related]
8. Activities of triazole-echinocandin combinations against Candida species in biofilms and as planktonic cells.
Chatzimoschou A; Katragkou A; Simitsopoulou M; Antachopoulos C; Georgiadou E; Walsh TJ; Roilides E
Antimicrob Agents Chemother; 2011 May; 55(5):1968-74. PubMed ID: 21343465
[TBL] [Abstract][Full Text] [Related]
9. The effect of the new triazole, voriconazole (UK-109,496), on the interactions of Candida albicans and Candida krusei with endothelial cells.
Fratti RA; Belanger PH; Sanati H; Ghannoum MA
J Chemother; 1998 Feb; 10(1):7-16. PubMed ID: 9531069
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of caspofungin and voriconazole against uncommon Candida spp.
Enache-Angoulvant A; Girard A; Poirot JL; Hennequin C
Int J Antimicrob Agents; 2009 Jun; 33(6):595-6. PubMed ID: 19162450
[No Abstract] [Full Text] [Related]
11. Anticandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes.
Baltch AL; Bopp LH; Smith RP; Ritz WJ; Michelsen PB
J Antimicrob Chemother; 2008 Dec; 62(6):1285-90. PubMed ID: 18772160
[TBL] [Abstract][Full Text] [Related]
12. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Chen TC; Chen YH; Chen YC; Lu PL
Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
[TBL] [Abstract][Full Text] [Related]
13. Difference in killing activity of caspofungin and paradoxical growth between Candida albicans and C. krusei clinical isolates in different media.
Varga I; Sóczó G; Kardos G; Kemény-Beke A; Kelentey B; Márton I; Majoros L
J Chemother; 2009 Feb; 21(1):36-41. PubMed ID: 19297270
[TBL] [Abstract][Full Text] [Related]
14. Postantifungal effect of the combination of caspofungin with voriconazole and amphotericin B against clinical Candida krusei isolates.
Oz Y; Kiremitci A; Dag I; Metintas S; Kiraz N
Med Mycol; 2013 Jan; 51(1):60-5. PubMed ID: 22746405
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method.
Pfaller MA; Hata K; Jones RN; Messer SA; Moet GJ; Castanheira M
Diagn Microbiol Infect Dis; 2011 Oct; 71(2):167-70. PubMed ID: 21696907
[TBL] [Abstract][Full Text] [Related]
16. Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with Neo-Sensitabs tablets.
Carrillo-Muñoz AJ; Quindós G; del Valle O; Santos P; Giusiano G; Ezkurra PA; Estivill MD; Casals JB
Chemotherapy; 2008; 54(1):38-42. PubMed ID: 18073469
[TBL] [Abstract][Full Text] [Related]
17. Interaction between caspofungin or voriconazole and cefoperazone-sulbactam or piperacillin-tazobactam by in vitro and in vivo methods.
Keçeli SA; Willke A; Tamer GS; Boral OB; Sonmez N; Cağatay P
APMIS; 2014 May; 122(5):412-7. PubMed ID: 24033828
[TBL] [Abstract][Full Text] [Related]
18. Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages.
Baltch AL; Bopp LH; Smith RP; Ritz WJ; Carlyn CJ; Michelsen PB
Diagn Microbiol Infect Dis; 2005 Aug; 52(4):299-304. PubMed ID: 15893901
[TBL] [Abstract][Full Text] [Related]
19. Liposomal amphotericin B displays rapid dose-dependent activity against Candida albicans biofilms.
Ramage G; Jose A; Sherry L; Lappin DF; Jones B; Williams C
Antimicrob Agents Chemother; 2013 May; 57(5):2369-71. PubMed ID: 23422915
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of antifungal combinations against Candida albicans biofilms.
Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
